DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant
JAMA · 07.03.2023 · 329 (9) · 745
DOI: 10.1001/jama.2023.1363 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JAMA, erschienen am 07.03.2023. Verfasst von Laura W Dillon und 20 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Neoplasm, Residual, Sequence Analysis, DNA. Die Arbeit wurde bisher 156-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Importance Preventing relapse for adults with acute myeloid leukemia (AML) in first remission is the most common indication for allogeneic hematopoietic cell transplant. The presence of AML measurable residual disease (MRD) has been associated with higher relapse rates, but testing is not standardized.
Objective
To determine whether DNA sequencing to identify residual variants in the blood of adults with AML in first remission before allogeneic hematopoietic cell transplant identifies patients at increased risk of relapse and poorer overall survival compared with those without these DNA variants. Design, Setting, and Participants In this retrospective observational study, DNA sequencing was performed on pretransplant blood from patients aged 18 years or older who had undergone their first allogeneic hematopoietic cell transplant during first remission for AML associated with variants in FLT3, NPM1, IDH1, IDH2, or KIT at 1 of 111 treatment sites from 2013 through 2019. Clinical data were collected, through May 2022, by the Center for International Blood and Marrow Transplant Research. Exposure Centralized DNA sequencing of banked pretransplant remission blood samples. Main Outcomes and Measures The primary outcomes were overall survival and relapse. Day of transplant was considered day 0. Hazard ratios were reported using Cox proportional hazards regression models.
Results
Of 1075 patients tested, 822 had FLT3 internal tandem duplication ( FLT3- ITD) and/or NPM1 mutated AML (median age, 57.1 years, 54% female). Among 371 patients in the discovery cohort, the persistence of NPM1 and/or FLT3 -ITD variants in the blood of 64 patients (17.3%) in remission before undergoing transplant was associated with worse outcomes after transplant (2013-2017). Similarly, of the 451 patients in the validation cohort who had undergone transplant in 2018-2019, 78 patients (17.3%) with residual NPM1 and/or FLT3 -ITD variants had higher rates of relapse at 3 years (68% vs 21%; difference, 47% [95% CI, 26% to 69%]; HR, 4.32 [95% CI, 2.98 to 6.26]; P < .001) and decreased survival at 3 years (39% vs 63%; difference, −24% [2-sided 95% CI, −39% to −9%]; HR, 2.43 [95% CI, 1.71 to 3.45]; P < .001). Conclusions and Relevance Among patients with acute myeloid leukemia in first remission prior to allogeneic hematopoietic cell transplant, the persistence of FLT3 internal tandem duplication or NPM1 variants in the blood at an allele fraction of 0.01% or higher was associated with increased relapse and worse survival compared with those without these variants. Further study is needed to determine whether routine DNA-sequencing testing for residual variants can improve outcomes for patients with acute myeloid leukemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
- Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
- Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
- Medical College of Wisconsin, Milwaukee.
- University of Virginia, Charlottesville.
- National Marrow Donor Program, Minneapolis, Minnesota.
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Dillon, L. W., Gui, G., Page, K. M., Ravindra, N., Wong, Z. C., Andrew, G., Mukherjee, D., Zeger, S. L., El Chaer, F., Spellman, S., Howard, A., Chen, K., Auletta, J., Devine, S. M., Jimenez Jimenez, A. M., De Lima, M. J. G., Litzow, M. R., Kebriaei, P., Saber, W., …, & Hourigan, C. S. (2023). DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. JAMA, 329(9), 745. https://doi.org/10.1001/jama.2023.1363
Vancouver
Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, et al. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. JAMA. 2023;329(9):745. doi:10.1001/jama.2023.1363
BibTeX
@article{Dillon2023,
author = {Dillon, Laura W and Gui, Gege and Page, Kristin M and Ravindra, Niveditha and Wong, Zoë C and Andrew, Georgia and Mukherjee, Devdeep and Zeger, Scott L and El Chaer, Firas and Spellman, Stephen and Howard, Alan and Chen, Karen and Auletta, Jeffery and Devine, Steven M and Jimenez Jimenez, Antonio Martin and De Lima, Marcos J G and Litzow, Mark R and Kebriaei, Partow and Saber, Wael and Weisdorf, Daniel J and Hourigan, Christopher S},
title = {DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant},
journal = {JAMA},
year = {2023},
volume = {329},
number = {9},
pages = {745},
doi = {10.1001/jama.2023.1363}
}
EUVIMED